Claims for Patent: 10,105,418

Summary for Patent: 10,105,418

Title:	Oral administration of tocilizumab treatment of autoimmune disease
Abstract:	The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering to the subject at an effective dose of tocilizumab.
Inventor(s):	Brod; Staley A. (Bellaire, TX)
Assignee:
Application Number:	14/139,122
Patent Claims:	1. A method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering tocilizumab to the subject; wherein said autoimmune condition is multiple sclerosis or rheumatoid arthritis. 2. The method of claim 1, wherein the tocilizumab is administered in a liquid form. 3. The method of claim 1, wherein the tocilizumab is administered in a solid form. 4. The method of claim 1, wherein tocilizumab is administered in a dose from 1.0 .mu.g to 50 .mu.g. 5. The method of claim 4, wherein tocilizumab is administered in a dose from 1 .mu.g to 10 .mu.g. 6. The method of claim 1, wherein said tocilizumab administration decreases levels of IL-6, Th1-like cytokines IL-2, IL-12, TNF-.alpha. and IFN-.gamma.. 7. The method of claim 1, wherein said tocilizumab administration increases levels of IL-4, IL-10 and IL-13. 8. The method of claim 1, further comprising administering a compound selected from the group consisting of a SIRS peptide, .alpha.-MSH, ACTH and SST. 9. A method for decreasing innate inflammatory cytokines IL-1.beta. and TNF-.alpha., Th1-like cytokines IL-2 and IFN-.gamma., IL-17 (T.sub.eff), IL-12p70 and increasing the Th2-like counter-regulatory cytokine IL-13 in a human subject comprising orally administering tocilizumab to the subject. 10. The method of claim 9, wherein the tocilizumab is administered in a liquid form. 11. The method of claim 9, wherein tocilizumab is administered in a solid form. 12. The method of claim 9, wherein tocilizumab is administered in a dose from 1.0 .mu.g to 50 .mu.g. 13. The method of claim 12, wherein tocilizumab is administered in a dose from 1 .mu.g to 10 .mu.g. 14. The method of claim 9, further comprising administering a compound selected from the group consisting of a SIRS peptide, .alpha.-MSH, ACTH and SST.

Details for Patent 10,105,418

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125276	01/08/2010		2039-02-26
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125472	10/21/2013		2039-02-26
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125472	11/19/2018		2039-02-26